Mazess R - Search Results

1

Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.

Liu G, Oettel K, Ripple G, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Marnocha R, Bruskewitz R, Mazess R, Bishop C, Bhattacharya A, Bailey H, Wilding G. Liu G, et al. Among authors: mazess r. Clin Cancer Res. 2002 Sep;8(9):2820-7. Clin Cancer Res. 2002. PMID: 12231522 Clinical Trial.

2

Vitamin D Supplements: Is Bone Loss by pQCT Really Negative?

Mazess RB. Mazess RB. J Bone Miner Res. 2021 Jun;36(6):1204-1205. doi: 10.1002/jbmr.4246. Epub 2021 Feb 3. J Bone Miner Res. 2021. PMID: 33534185 Free article. No abstract available.

3

Vitamin D: Bolus Is Bogus-A Narrative Review.

Mazess RB, Bischoff-Ferrari HA, Dawson-Hughes B. Mazess RB, et al. JBMR Plus. 2021 Oct 30;5(12):e10567. doi: 10.1002/jbm4.10567. eCollection 2021 Dec. JBMR Plus. 2021. PMID: 34950828 Free PMC article.

4

Letter to the editor in response to the article: "Vitamin D concentrations and COVID-19 infection in UK biobank" (Hastie et al.).

Davies G, Mazess RB, Benskin LL. Davies G, et al. Among authors: mazess rb. Diabetes Metab Syndr. 2021 Mar-Apr;15(2):643-644. doi: 10.1016/j.dsx.2021.02.016. Epub 2021 Feb 9. Diabetes Metab Syndr. 2021. PMID: 33722481 Free PMC article. No abstract available.

5

Reply to: Vitamin D: A single initial dose is not bogus if followed by an appropriate maintenance intake.

Mazess RB, Bischoff-Ferrari HA, Dawson-Hughes B. Mazess RB, et al. JBMR Plus. 2022 Feb 17;6(3):e10605. doi: 10.1002/jbm4.10605. eCollection 2022 Mar. JBMR Plus. 2022. PMID: 35309858 Free PMC article. No abstract available.

6

1,24(S)-dihydroxyvitamin D2, an endogenous vitamin D2 metabolite, inhibits growth of breast cancer cells and tumors.

Zinser GM, Tribble E, Valrance M, Urben CM, Knutson JC, Mazess RB, Strugnell SA, Welsh J. Zinser GM, et al. Among authors: mazess rb. Anticancer Res. 2005 Jan-Feb;25(1A):235-41. Anticancer Res. 2005. PMID: 15816543 Free article.

7

A review of intravenous versus oral vitamin D hormone therapy in hemodialysis patients.

Mazess RB, Elangovan L. Mazess RB, et al. Clin Nephrol. 2003 May;59(5):319-25. doi: 10.5414/cnp59319. Clin Nephrol. 2003. PMID: 12779092 Review.

8

The bone mineral density of the right and left femur in a large group of white women.

Mazess RB. Mazess RB. Osteoporos Int. 2001;12(3):249-50. doi: 10.1007/s001980170137. Osteoporos Int. 2001. PMID: 11315245 No abstract available.

9

Peak bone mass, reference values, and T-scores.

Mazess RB. Mazess RB. J Clin Densitom. 2001 Spring;4(1):73-7. doi: 10.1016/s1094-6950(06)60153-4. J Clin Densitom. 2001. PMID: 11309522 No abstract available.

10

PTH treatment: safety studies needed.

Mazess RB. Mazess RB. Calcif Tissue Int. 2000 Dec;67(6):480. Calcif Tissue Int. 2000. PMID: 11289699 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

189 results

Search Page

Filters